Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Cyst Fibros. 2020 Jun 11;19(5):746–751. doi: 10.1016/j.jcf.2020.04.010

Figure 2. Ussing chamber measurements of CFTR activity in HBEs (F508del/F508del) treated with CFTR modulators.

Figure 2.

A) Forskolin peaks measured by short-circuit current (Isc) were elevated in both treatment arms (Teza/Iva, Luma/Iva) compared to vehicle (DSMO) control for the duration of both the treatment and washout phases. Forskolin peaks reached maximum at day 7 of the treatment arms. B) CFTRinh172 inhibition was accentuated in both treatment arms compared to vehicle (DMSO) control during both treatment and washout phases. CFTRinh172 inhibition reached maximum at day 7 of the treatment arm. C) Transepithelial resistance (Rt) demonstrates that the cell monolayer remained intact over the course of the treatment period, indicating no toxic effects of the drugs compared to the vehicle (DMSO) control group. *, + indicate level of significance between vehicle and treatment groups at the specified time point.